Document is current

Article History

Received: 29 October 2021

Accepted: 25 July 2022

First Online: 19 August 2022

Declarations

:

: M.K., J.M., and L.M. declare an unrestricted research grant at IoPPN and SLaM from Indivior via Action on Addiction for a randomised controlled trial of personalised PSI among treatment-resistant patients enrolled in OUD SOC (published in 2019).J.M. declares research grants from the National Institute for Health Research (NIHR; randomised controlled trial of depot naltrexone for OUD, and a randomised controlled trial of acamprosate for AUD) and the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Mental Health Foundation Trust (SLaM; randomised controlled trial of novel cognitive therapy for cocaine use disorder). J.M. is a clinical academic consultant for the US National Institute on Drug Abuse, Centre for Clinical Trials Network, and he was Senior Academic Advisor for the Alcohol, Drug, Tobacco, Justice Division, Health Improvement, Public Health England (to September 2021). He received honoraria and travel support from Reckitt-Benckiser (2016; treatment of OUD) and from PCM Scientific and Martindale for the Improving Outcomes in Treatment of Opioid Dependence conference (2018 and 2021).F.C. declares co-applicant status for the Tenovus Scotland Research Grant for examining the impact of the UK Government’s reclassification of gabapentinoids.The other authors declare that they have no competing interests.